Technology

In fact, vaginal rings constitute a perfect long acting drug delivery technology. The technology releases pharmaceutical ingredients at a predetermined rate over a long period of time, e.g. from one month up to five years.

At VaRi Bioscience we focus on indications that require long-term treatment, low day to day plasma level variations, and sustained drug exposure.

Vaginal rings are based on a polymer technology, an established and well-known process technology. Two core technologies are needed for the manufacturing of vaginal rings:

The extrusion process is based on long-lasting experience in the plastic industry. Various approaches for the molding technology have been developed. VaRi Bioscience is collaborating with specialized CMOs for clinical and commercial supply.

Resorption through the vaginal epithelium allows for a `direct´ delivery of the drug to the bloodstream. The bypass of the gastrointestinal tract and the first pass effect in the liver reduces metabolic losses of the active ingredient as well as the metabolic burden for the liver. As a consequence, very small amounts of the active ingredient need to be released, thus increasing product tolerability and reducing the occurrence of side effects.